bioSyntagma, LLC, a precision medicine company, has been awarded a nearly $200,000 Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop a new platform for mapping multi-omic biomarkers from single-cells in cancer patient biopsies. bioSyntagma’s Principal Scientist, Dmitry Derkach, M.D., Ph.D., is the Principal Investigator for the project. Continue reading
Author Archive: AZBio
AZBio In the Loop for the Week of March 19, 2018
|
Senate Proclamation Honors Arizona Bioscience Community
On March 15, 2018, the Arizona Senate recognized the work of the members of Arizona’s Bioscience Community with a Senate proclamation. Continue reading
TGen tests ultrasound as way to enhance cancer drug delivery
Sound waves drive drug therapies to cancer cells; minimize toxicity
Castle Biosciences Announces Receipt of New York Laboratory Permit
Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that it has received its Clinical Laboratory Permit from the New York State Department of Health, including approval for three clinical tests. The receipt of the New York permit allows patients in that state to benefit from the Company’s DecisionDx®-Melanoma, DecisionDx®-UM and DecisionDx®-PRAME molecular diagnostic tests that provide actionable molecular information to inform patient care decisions.
Applications are open for the National Medal of Technology and Innovation
The National Medal of Technology and Innovation (NMTI) is now accepting nominations for 2018. Awarded by the President of the United States, the NMTI is the nation’s highest honor for technological achievement. If you know of an individual, team, or company that has made an outstanding technological contribution to United States’ economic, environmental, or social well-being, you can submit nominations until the April 6 deadline. The nomination form, a sample recommendation letter, and FAQs are available on the NMTI website.Continue reading
Destroy Pancreatic Cancer dedicates $1 million for unique TGen-designed clinical trial
Destroy Pancreatic Cancer, an Atlanta-based non-profit dedicated to finding better treatments for the most deadly of all cancers, is donating $1 million for a unique pancreatic cancer clinical trial designed by the non-profit Translational Genomics Research Institute (TGen).Continue reading
Focus On Lyme Foundation Builds Biorepository Consisting of Chronic Lyme Disease and Post-Treatment Lyme Disease Syndrome (PTLDS) Donors
When Focus on Lyme put out the call for volunteers willing to donate blood samples for research on Lyme disease, the entire day’s schedule was filled within minutes. Some participants, many quite ill, traveled hundreds of miles just to make a blood donation.Continue reading
Learn what’s next at Flinn
In the Flinn Foundation’s new report, President and CEO Tammy McLeod looks ahead at how the Foundation’s programs can make a difference across Arizona. Continue reading